Septerna Inc (SEPN)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Septerna Inc currently loses $49.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 9
in 60 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About Septerna Inc
Septerna Inc, listed on NASDAQ as SEPN, is a biotechnology company that discovers and develops oral small molecule medicines targeting G protein-coupled receptors. Its work centers on endocrinology, immunology and inflammation, and metabolic disease, and it generated $46.0 million of revenue in FY2025.
Today's Snapshot
SEPN closed 1.6% higher at 37.97. Wells Fargo, an investment bank, kept its Buy rating and $50 price target for Septerna.
Trading Volume
Above 10d avg 299.0K
475.2K
vs S&P 500 Today
Outperforming Market
+2.09%
Updated: September 10, 2026 at 12:06 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$30.32 - $38.91Buy
- RSI (14)46.44Neutral
- Stochastic %K (14, 3, 3)14.81Buy
- MACD Level (12, 26)-0.34Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.